CLV IntelligenceReimbursement Policy Monitoring

Code intelligence

FDA-BLA761067 reimbursement alerts

Policy changes, MAC LCD updates, and CMS guidance matched to code FDA-BLA761067.

Elevated code risk

Signal breakdown

1 shown · 1 total in platform

Risk: Elevated
0

Critical

0%

1

High

100%

0

Routine

0%

0

Low

0%

New this month

—

alerts added in last 30 days

Effective soon

—

no upcoming deadlines

FDA Approval: ILUMYA (TILDRAKIZUMAB-ASMN) — Type 1 - New Molecular Entity

Policy FDA-BLA761067 · Dermatology

High

Ilumya (tildrakizumab-asmn) is an injectable interleukin-23 antagonist approved for plaque psoriasis, administered via subcutaneous injection in a physician office or clinical setting, supporting Part

View alert

Audit documentation

Building an audit file that includes FDA-BLA761067?

The Tripwire Audit Pack exports 12 months of Dermatology policy-change history — every alert with a link to its government source document, as a formatted PDF for compliance distribution plus a machine-readable CSV. Delivered automatically after payment. No account, no call.

Get the Dermatology audit pack — $349One-time purchase · not a subscription